Albert Kandra
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Risk factors and management of pasireotide-associated hyperglycemia in acromegaly.
Journal: Endocrine connections
Published: October 21, 2020
Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available.
Journal: Leukemia & lymphoma
Published: July 31, 2019
Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.
Journal: Endocrine
Published: August 09, 2016
Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.
Journal: Endocrine
Published: December 15, 2015
Time of administration important? Morning versus evening dosing of valsartan.
Journal: Journal of hypertension
Published: September 27, 2014
Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.
Journal: European journal of heart failure
Published: August 03, 2014
Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study.
Journal: European journal of heart failure
Published: June 22, 2013
Changes in aortic pulse wave velocity in hypertensive postmenopausal women: comparison between a calcium channel blocker vs angiotensin receptor blocker regimen.
Journal: Journal of clinical hypertension (Greenwich, Conn.)
Published: November 07, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026